When will Sparsentine be released?

Sparsentan (Sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA) produced by the US biopharmaceutical company Travere Therapeutics. The main effects of this drug are to protect glomerular podocytes and reduce proteinuria, which it does by antagonizing endothelin and angiotensin receptors. In clinical trials, sparsentane has shown significant effectiveness in reducing proteinuria, particularly in high-risk adult patients with primary immunoglobulin A nephropathy (IgAN) and rapidly progressive disease.

Specifically, in a phase 3 clinical trial calledPROTECT, researchers compared the efficacy of sparsentan and irbesartan. The results showed that compared with irbesartan, the urinary protein to creatinine ratio decreased more in the sparsentan treatment group, indicating that sparsentan was more effective in reducing proteinuria.

However, some adverse reactions may occur when using sparsentane, such as hypotension, peripheral edema, dizziness, etc., so it needs to be used under the guidance of a doctor.

As for the time when Spasentan will be launched in China, there is no definite news yet. Although the drug has been approved and marketed in other countries, in China, the launch of new drugs requires strict approval procedures, including clinical trials, drug review and other links. Therefore, the launch time of sparsentin in China may be affected by a variety of factors, such as approval progress, market demand, etc.

In summary, sparsentan, as a new drug for the treatment of proteinuria, has significant clinical effects. However, patients still need to follow medical advice and pay attention to the adverse reactions of the drug when using it, and hope that the drug will be launched in China as soon as possible to bring good news to more patients.